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Abstract
The Branislav “Brano” Radovancevic Heart Failure Forum (BHFF) was established
in 2008. Each year, experts in the field of heart failure gather to learn, discuss and
debate the recent advances and theories related to diagnostics and therapeutics.
The 12th Annual BHFF was held September 18-21, 2019, in Belgrade, Serbia, and
was attended by over 350 participants from 15 countries. Over four days,
seventeen separate sessions focused on challenges and solutions related to
mechanical circulatory support and heart transplantation. For the first time, a
summary of selected presentations was organized and presented herein.
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Mechanical Circulatory Support and Heart Transplantation
Over the past sixty years, there has been considerable progress in developing
durable mechanical circulatory support (MCS) systems. Multiple international MCS
registries report data from patients receiving durable MCS devices in all
participating countries and hospitals.1, 2 INTERMACS and PediMACS (US),
EUROMACS (Europe), J-MACS (Japan), and UK MCS Registry (United Kingdom)
have combined data input into the ISHLT (IMACS) Worldwide Registry. Data from
almost 20,000 patients have been entered into this registry. Trends in survival
rates continue to rise, with 1-year survival at 90% and 4-year survival at 54%. The
improving survival is attributed to a decline in adverse event rates. Novel energy
transfer systems for durable left ventricular assist devices (LVAD) represent the
latest advances that will likely continue improving outcomes.
Heart transplantation remains the treatment of choice for end-stage heart failure,
but serious challenges remain. Limiting heart transplant factors include donor
shortages, allograft vasculopathy, complications from immunosuppression,
antibody-mediated rejection, and increasingly complicated recipients. Future
alternatives to heart transplantation may involve durable LVADs,
xenotransplantation, stem cell therapy, and whole-organ bioengineering. Ex-vivo
organ preservation systems can improve donor allocation by allowing up to 12
hours of donor organ preservation.3 Needed improvements in post-transplant
patients include avoidance and treatment of allograft vasculopathy, malignancies,
renal dysfunction, and better immunosuppression.
Despite advances in medical therapies to treat heart failure, the hospitalization rate
has not changed significantly since 2000. Heart failure continues to be a significant
driver of overall health care costs, with the global cost estimated to increase to
$170 billion by 2030. Nearly every new payment model requires hospitals and
physicians to work collaboratively with mutual accountability for long-term quality
and costs. Hospitalization accounts for 50% of this cost, and with all-cause
readmission rates of 50% within 6-months, improving out-of-hospital care is
crucial.4-6 Real-world use of the CardioMEMS™ HF System reduces heart failure
hospitalizations and comprehensive hospitalization costs. Focusing on the
economic processes within a program should lead to cost savings and revenue
increases. Understanding how much money each cardiovascular (CV) service
contributes per day helps hospital administration know what to resource
appropriately.
As the prevalence of heart failure continues to rise worldwide, research and
development of novel therapies is a continuing challenge. Researchers need to be
aware of the spectrum of funding sources and obtain funds for basic and applied
research programs. Phase III trials in the global setting are needed, but there
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needs to be a focus on Phase I and Phase II as well. Investment in single-site
investigations, which are the foundation for the Phase III trials. Heart failure needs
well-designed trials to reduce the failure rate of Phase III studies.

Important Elements of a Successful MCS and Heart Failure
Program
The established goals of heart failure management are improving symptoms and
quality of life, slowing the progression of CV dysfunction, and reducing mortality.
Keys to successful treatment are to employ a multidisciplinary approach, properly
select patients for treatments, comprehensive patient management, and provide
psychosocial support. Improved outcomes will result from improvements in patient
selection, technology, and patient management. LVADs improve survival, healthrelated quality of life, and functional status but are associated with major adverse
events in a substantial percentage of patients. The incidence of adverse events
varies between devices and by the indication for LVAD implantation. Reducing
device-related complications in the future requires control of risk factors, improved
surgical implantation techniques, and advances in LVAD technology.
Gastrointestinal (GI) bleeding is the number one cause of hospital readmission in
outpatients with LVAD support.7 Approximately 20% to 40% of patients supported
by a CF LVAD bleed from the GI tract (7.8 events/100 patient-months).8 All
anticoagulants should be discontinued upon admission for GI bleeding and are
restarted after complete resolution of bleeding with a targeted INR towards the
lower end of the range. Aspirin is usually restarted after the cessation of GI
bleeding. Octreotide is capable of stabilizing GI bleeding by causing splanchnic
vasoconstriction and improved platelet aggregation.9, 10
The development of right ventricular failure (RVF) in LVAD recipients is associated
with increased morbidity and mortality. The preoperative state of the right ventricle
(RV) is important to establish. RVF exists in approximately 25%-40% of patients
with implanted LVADs. The incidence of RVF after LVAD placement is difficult to
assess due to the lack of a common definition. Communication among the
perioperative team may be beneficial for the early initiation of temporary rightsided MCS to avoid RVF-related complications.
Levosimendan (calcium sensitizer) has a positive inotropic effect by increasing the
affinity of myocardial troponin C to calcium and does not occur at the expense of
calcium overload or increased myocardial oxygen demand. Vasodilation occurs in
both arterial and venous smooth muscle cells, causing reduction in both RV
preload and afterload. There is cardioprotection by reducing ischemia-reperfusion
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injury, apoptosis, and oxidative stress. Levosimendan has a favorable inotropic
and vasodilatative effect on RV function and systemic circulation for several days
in LVAD patients.
Patients with congenitally-corrected transposition of great arteries (ccTGA) often
present with heart failure in the fourth or fifth decade of life. Implantation of an
LVAD in the systemic ventricle has been described in small groups of patients.
Accurate imaging (transthoracic echocardiography [TTE] with contrast,
transesophageal echocardiography, and cardiac multi-slice computed tomography)
is essential in successfully implanting small-sized intrapericardial LVADs in
patients with complex anatomies, such as ccTGA and dextrocardia. Implantation is
technically challenging but feasible.
Mitral valve (MV) repair along with coronary artery bypass graft (CABG) surgery in
patients with severely depressed LV function provides favorable midterm survival
results. Frequently, the MV has some degree of papillary muscle dysplasia and
leaflet underdevelopment that goes undiagnosed by echocardiography exam or
during valve analysis. The incidence of papillary muscle dysplasia and leaflet
underdevelopment increases with ischemic heart disease. This is the reason that a
reduction annuloplasty in patients with severely depressed LV function has a high
mitral regurgitation (MR) recurrence. To choose the appropriate repair technique in
patients with severely depressed LV function, the subvalvular apparatus and
leaflets should be carefully examined.

Update on Regional End-Stage Heart Failure Program
Brief reports on the status of durable and short-term MCS and heart
transplantation were given for centers in Italy, Hungary, Croatia, Macedonia,
Slovenia, and Serbia. Generally, the volume of these therapies is increasing at a
fast pace with improving outcomes.

Heart Failure Management
There are many unmet needs in the management of acute and chronic heart
failure. The prevalence of advanced heart failure in the United States is now
estimated at 5.7 million people and is expected to increase by 46% in the next ten
years.11 Opportunities for improvements in therapy for advanced heart failure
include innovative new drugs, increasing the donor heart pool, and expanding the
application of MCS. Opportunities for improving the care of cardiogenic shock
involve earlier use of MCS, safer technology, and more durability.
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Current heart failure management involves attention to MV function. Approximately
20% of patients admitted with advanced heart failure have moderate to severe
MR. First-line therapy is optimal medical management; for persistent degenerative
MR, surgery is necessary. Patients with 3+ MR despite medical therapy should be
assessed for percutaneous therapies. There are numerous evolving treatment
options for functional MR.12
No two advanced heart failure patients are the same, which requires diverse,
individualized therapy regimens that consider underlying etiology, patient
preferences, genotypes, and financial realities. Medical therapies needs include a
safe oral inotrope, a simpler oral vasodilator, better antiarrhythmics, and drugs that
decrease the heart rate. Cardiac resynchronization therapy (CRT) needs to be
refined by determining which patients will benefit from the therapy, optimal lead
placement, and optimal device settings. MCS continues to evolve to improve the
quality of life. Regenerative and replacement therapies continue to improve and
play an expanding role in the treatment regimens. For 2019, biologic replacement
of the heart remains the best option.
EUROMACS is a large international registry of data from patients supported by
durable MCS that enables clinical research.13 Regular reports enable comparisons
among participating centers and other registries. There are 71 participating centers
in 21 countries with over 5000 patient entries. Pediatric patients comprise 6.5% of
all patients, and 81% are males. Indications for LVAD implantation include bridge
to transplant (36%) or to candidacy (33%), destination therapy (15%), rescue (7%),
recovery (4%) and other (5%). Major infection (48%) and bleeding (20%) are the
most frequent adverse events reported. Ten publications report the details from
this registry.

Hot Topics in Heart Failure
There are a number of challenges related to recovery after temporary MCS.
Currently, there is no clear definition of myocardial recovery. Objective measures
for clinically meaningful ventricular unloading that will optimize recovery are
needed. There is a need for novel MCS device designs and control strategies that
could enhance myocardial recovery. Objective measures of unloading and
reloading of myocardium using advanced imaging modalities and sensors,
metabolic techniques, and physiological data need to be defined. Recovery rates
with LVADs are highly variable, and post‐explant outcomes appear
heterogeneous. Comparisons of studies are difficult because of differing heart
failure etiologies, durations of failure, follow‐up periods, patient selection, weaning
strategies, and definitions of recovery.
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Recovery of myocardial function during LVAD support provides insight into the
inflammatory triggers in heart failure. Multiple inflammatory pathways are active
during the injury phase and during repair. During LVAD support, decreasing
inflammation is a very strong signal of the repair process. Inflammatory responses
activate epithelial mesenchymal transition hat contributes to fibrosis during heart
failure. Inflammation is a dynamic process in the progression of heart failure.
Myocardial samples taken before and after LVAD procedures are of great value to
study the biology of human heart failure.
The REVIVE-IT clinical trial was designed because an unmet clinical need exists
for heart failure patients who remain symptomatic with a depressed ejection
fraction despite conventional medical therapy.14 Equipoise exists for designing a
clinical trial with circulatory assist devices in less-ill patients with the current
generation of LVADs. However, equipoise was disrupted by concerns over
adverse events. In the current state of MCS technology, with the exception of right
heart failure, better “risk” status at implant provides limited or no “protection”
against serious adverse events. The major advantage of an LVAD over medical
therapy is in the quality of life; however, ischemic stroke is six times more common
and hemorrhagic stroke is three times more common in LVAD vs medical therapy.
Equipoise for another clinical trial requires continued improvement in stroke
reduction with a stroke rate close to 5%.

Acute MCS
Extracorporeal membrane oxygenation (ECMO) is the best option in acute
cardiopulmonary failure because it can be:
• applied for cardiac and pulmonary failure
• converted to cardiopulmonary bypass for subsequent surgery
• converted to temporary LVAD or RVAD
• converted to RVAD after permanent LVAD implantation
• used for varying durations
• less expensive than other therapies
• used for bridge to decision, bridge to recovery, bridge to transplant, or
bridge to durable LVAD 15
Based on experience in Croatia, ECMO should be a nationwide primary
resuscitation tool as it is lifesaving with a very favorable success rate. Because
timing of implantation is critical, this lifesaving opportunity should be funded by the
national healthcare system, and intensive and aggressive education should be
organized nationwide to utilize all of the potential of the technology.
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Anticoagulation during ECMO support normally includes an initial bolus of 5,000 to
10,000 units of heparin and maintenance infusions to maintain the activated
clotting time (ACT) at 180 to 200 seconds and the partial thromboplastin time
(PTT) at 60 to 80 seconds. The negative effects of heparin include excessive
bleeding when the PTT is greater than 90 seconds, heparin-induced
thrombocytopenia in 5% of patients and a reduction in antithrombin levels. Platelet
activation occurs due to high shear stress, mostly at tubing connecter sites.
Studies indicate that low does or discontinuation of heparin during ECMO is
feasible in some patients, but this requires more research.
LV distension due to increased afterload during VA-ECMO can result in pulmonary
edema and poor myocardial recovery. Venting of the LV with an Impella device
(Abiomed) during veno-arterial (VA) ECMO support may alleviate LV distension;
however, the benefits of this approach are unknown. Patients receiving an Impella
device that are later escalated to VA ECMO support demonstrated significantly
lower mortality than patients who received VA ECMO support first. Patients who
require cardiopulmonary resuscitation before Impella or VA ECMO have the worst
survival. The beneficial effects of a primary versus secondary LV unloading
strategy with the Impella device has to be evaluated in prospective, randomized
trials.
The use of an Impella 5.0 device as a bridge-to-bridge in patients classified as
INTERMACS profile 1 may offer a survival benefit. At Memorial Hermann Hospital,
the percentage of patients in INTERMACS profile 1 before LVAD implantation is
considerably higher than reported in the INTERMACS Registry (42% vs. 18%);15
however, the short- and long-term survival rates are equivalent. Despite inotropic
support, many patients cannot be hemodynamically stabilized and have refractory
low-cardiac output. Long-term assist devices are an expensive option, and their
implantation is complicated by a high rate of right heart failure and mortality.
Bridging patients with a short-term MCS is intended to stabilize hemodynamics
and improve end-organ function. This tactic may improve survival and reduce
surgical risk as more time is allowed for a thorough evaluation of options and
prognosis.
For patients who are stable on acute MCS but require continuous support, there
are a variety of options with different expected outcomes. A durable LVAD or heart
transplant may be suitable for select patients, but major surgical risk, organ
availability, and known complications may limit those options option. Ambulatory
support with the Intravascular Ventricular Assist System (iVAS) uses a minimally
invasive technique and has a short recovery time. The iVAS can be stopped
temporarily, maintenance and troubleshooting are non-emergent, and there is no
need for a continuous caregiver. During support, the iVAS increases coronary
blood flow, decreases left ventricular afterload, and promotes myocardial recovery.
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A select group of patients with myocardial reserve can be supported for long
durations, rehabilitated, and discharged from the hospital.
Frailty is the state of increased vulnerability to physiologic distress and is distinct
from aging, comorbidity and disability. A specific frailty measure needs to be
developed and validated for the advanced heart failure population. The tool should
measure typical features of frailty and assist in distinguishing heart failure-related
debility versus frailty-related debility. Ideally, the measure of frailty would predict
clinical outcomes after LVAD and the rehabilitation potential of patients. There is a
growing population of older adults being considered for transplant or LVAD
candidacy. While multiple frailty scores exist, there is not a broad consensus on
how and when to use them. Further, many are burdensome – either in manpower,
time or tools. Presently, there is a lack of evidence for frailty measures efficacy in
the advanced heart failure population.

LVAD Complications
von Willebrand Factor (vWF) is a multimeric protein that binds collagen on
vascular sub-endothelium and platelets. High molecular weight multimers (HMWM)
of vWF are more active in mediating platelet adhesion and aggregation. Acquired
von Willebrand Syndrome (AvWS) is a disorder characterized by decreased
HMWM. Loss of vWF HMWM is attributed to shear damage in LVADs and is
associated with GI bleeding during support with axial and centrifugal flow LVADs.
Degradation of vWF HMWM was seen in both types of pump with significantly
greater preservation of vWF HMWM seen with HeartMate 3 (Abbott) compared to
HeartMate II (Abbott). Functional attributes of vWF (antigen and activity) are within
normal range post-LVAD, although “normal” values post-LVAD may need to be
defined. vWF HMWM alterations, but not functional changes, are closely
correlated with episodes of bleeding and non-surgical bleeding in HeartMate 3.
There is emerging evidence of angiotensin inhibition and incidence of GI bleeding
during LVAD support. GI bleeding is common during LVAD support and is
observed in 25% - 40% of patients. The significant morbidity from GI bleeding
includes blood transfusion with allosensitization and the potential increase in
thromboembolic events. GI bleeding is associated with hospitalization, reduced
anticoagulation intensity, and the need for blood product transfusion. Angiotensin II
antagonism is associated with a reduced risk of GI bleeding caused by
arteriovenous malformations in patients supported by an LVAD.16 Studies indicate
that angiotensin II receptor blockers or angiotensin converting enzyme inhibitors
should be prescribed to patients with the continuous flow (CF) LVADs to reduce
afterload and potentially reduce GI bleeding.17 Further study should be randomized
and focus on comparative efficacy between therapeutic classes of medications.
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GI bleeding is the most common cause of morbidity and rehospitalization in
patients supported by a CF-LVAD. GI bleeding decreases the quality of life and
increases the risk of thromboembolism. Gastrointestinal angiodysplasia (GIAD) are
leaky, proliferative, thin-walled vascular channels without adequate pericyte
support and account for 5% of the GI tract's bleeding lesions in the general
population. GIADs are responsible for 60% of confirmed GI bleeding in patients
with CF-LVADs. Inhibition of the HIF1a pathway with digoxin restores the balance
of angiogenic factors with a decrease in Ang-2 and VEGF and an increase in Ang1. Digoxin may prevent GIAD-related bleeding in CF-LVAD patients by preventing
pathological angiogenesis in intestinal mucosa and stabilization of preexisting
lesions.
Based on the German Heart Center Berlin experience, a comparison of adverse
events and outcomes between the HeartWare ventricular assist device (HVAD,
Medtronic) and HeartMate 3 was reported. The HVAD supported over 900
patients, and more than 160 patients received the HeartMate 3. The rates for
pump thrombosis, cerebral bleeding, and total stroke were significantly better for
the HeartMate 3, whereas the driveline infection rate was lower for the HVAD
supported patients. The rate of GI bleeding was not different between the two
devices. The HVAD was associated with more cerebral bleeding and pump
thrombosis than the HeartMate 3, resulting in a higher hemocompatibility-related
adverse event score, especially after one year of support. The HeartMate 3 had a
higher rate of outflow graft twist. The overall survival rate was similar between the
two devices.

Challenges in Mechanical Circulatory Support
One cause of driveline failure in the HeartMate II is damage to the percutaneous
lead's wiring insulation resulting in an electrical short to ground, referred to as a
short-to-shield (STS). When there is a break in the outer insulation of one of the
conductors, there is the potential for unintended electrical contact between the
wire strands and the metal-braided shield, resulting in an STS. This condition can
result in speed reduction and pump stoppage when the pocket controller is
connected to an alternating current or a grounded power source such as the
mobile power unit and power module. Nearly 15% of patients implanted with the
HeartMate II have experience percutaneous lead damage.18 Since pump
replacement is usually not associated with high mortality, it should be considered,
especially in destination therapy patients. Patients and their families need to be
well informed regarding the benefits and risk of LVAD replacement versus staying
with an ungrounded cable.

The VAD Journal: 2019 BHFF Conference Proceedings Summary

Page 9 of 23

The VAD Journal: The journal of mechanical assisted circulation and heart failure

Complex infections during support with an LVAD are difficult to manage and add to
the cost of care. For severe device infections, the first priority is drainage and
debridement of the infected site. The second priority is microbial suppression and
sterilization with supplemental topical means, including irrigation and lavage
systems. Antibiotic beads may be effective in treating severe LVAD site infections.
Omental flaps to vascularize the infection site have also been shown to be
effective in some patients.
During LVAD support, pumping integrity depends on competent native heart
valves. The International Soceity of Heart and Lung Transplantation Guidelines
recommends that patients with more than mild aortic insufficiency should promptly
be considered for surgical intervention during device implantation. The incidence
of aortic insufficiency is high in LVAD-supported patients (37%).19 For severe
aortic regurgitation, the aortic valve may be closed at implantation.20 Tricuspid
valve regurgitation should be corrected, especially if atrial fibrillation, a dilated
annulus greater than 42 mm, and a small left ventricle are present. Some patients
will continue to have or develop MR after LVAD implantation, which negatively
affects RV function, LVAD filling, and possibly survival. Acquired aortic
insufficiency is better tolerated with a competent MV. Mitral repair associated with
LVAD support does not increase operative mortality, reduces long-term MR, and
can decrease RV failure rates.
Appropriate treatment of biventricular failure requires specific considerations
during the assessment phase. Biventricular failure is common in many patients
that present with advanced stage heart failure. The diagnosis of biventricular
failure involves elevated right atrial pressure, peripheral edema, renal dysfunction,
and hepatic dysfunction. Patients with biventricular failure are in INTERMACS
profile 1 or 2 with treatment consisting of ECMO, intra-aorta balloon pump, and
multiple inotropes. In determining the appropriate treatment approach, candidacy
for transplant or destination therapy should be considered. The etiology and
reversibility of failure should be determined, and the most appropriate MCS device
for meeting the ultimate goal must be carefully chosen.

Challenges in Heart Failure Interventions
Implantable cardioverter defibrillators (ICD) are recommended to reduce the risk of
sudden death in select patients with heart disease. The risk of sudden death has
been reduced by 44% since the introduction of ICD therapy and the
implementation of new heart failure medications. Prophylactic ICDs in patients with
symptomatic, non-ischemic heart failure is not associated with a significantly lower
long-term rate of all-cause death. The association between ICD use and survival
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decreased linearly with increasing age. ICD for primary prevention is underused,
although it is associated with reduced short- and long-term all-cause mortality.
In the STICH trial, patients with an ejection fraction <35% and coronary artery
disease amenable to CABG were randomly assigned to medical therapy alone
(602 patients) or medical therapy plus CABG (610 patients). The primary outcome
was the rate of death from any cause. Secondary outcomes included death from
CV causes, death from any cause, and hospitalization for CV causes. There was
no significant difference between medical therapy alone and medical therapy plus
CABG with respect to the primary endpoint. Patients assigned to CABG had lower
rates of death and hospitalization. In patients with ischemic cardiomyopathy, the
primary and secondary outcomes were significantly lower over ten years among
patients who underwent CABG in addition to receiving medical therapy than those
who received medical therapy alone.
Clinical trials studying transcatheter aortic valve implantation (TAVI) have mostly
involved older patients; however, this treatment may be suitable for younger
patients. Guidelines include comprehensive diagnostic and treatment options,
multidisciplinary teams, networking among hospitals, strong communication
structure, and regular assessment of various interventions. Ongoing investigations
are destined to expand indications for TAVI towards lower-risk, younger, and
asymptomatic populations. Before TAVI can be widely used in younger patients, it
must demonstrate long-term durability equivalent to surgical bioprostheses.
Strategies are needed for managing structural valve deterioration, reducing the
requirement for permanent pacemaker implantation, and ensuring minimal
incidence of paravalvular leak. Overall, TAVI appears poised to be the preferred
strategy for aortic valve replacement in most patients.21
Percutaneous mitral interventions are variable in outcomes as there are numerous
mitral devices and ongoing clinical trials. In the MITRA-FR clinical trial, patients
with severe MR and ineligible for mitral surgery were randomized between
MitraClip (Abbott, Chicago, IL) plus medical therapy or medical therapy alone.22 No
difference was observed in the composite endpoint of all-cause death and
rehospitalization for heart failure. The COAPT trial, a multicenter trial in patients
with heart failure and moderate-to-severe (3+) or severe (4+) secondary MR who
remained symptomatic despite maximally-tolerated guideline-directed medical
therapy (GDMT) were also randomized between MitraClip plus GDMT or GDMT
alone.23 In this study, there was a significant difference in all-cause mortality and
hospitalization favoring the MitraClip plus GDMT. Continuing studies evaluating
various devices and techniques are necessary to define the utility of percutaneous
mitral interventions better.
The best surgical treatment for secondary MR remains controversial. Mitral repair
performed with an undersized rigid complete ring to restore leaflet coaptation and
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valve competence has been considered the standard treatment. This procedure
can be performed with acceptable perioperative risk in carefully selected patients
with secondary MR and poor LV function. Several predictors of failure after repair
have been recognized in the last decade, and it is well known that more advanced
leaflet tethering predicts significant recurrence. To improve MV repair durability,
concomitant techniques on the subvalvular apparatus have been described. Small,
non-randomized, and observational studies have assessed secondary chordal
resection suturing of the posteromedial papillary muscle to the aorto-mitral
continuity, infarct plication, papillary muscle imbrication, and posteriori LV
restoration. No study has convincingly demonstrated a survival benefit compared
with medical therapy in patients with MR and LV systolic dysfunction; this argues
against surgical intervention in asymptomatic patients and poses a complex
surgical decision in high-risk cases.

MCS Management
Multimodality imaging is necessary to guide LVAD patient management.
Computed tomography (CT) is useful to detect thromboembolism, aortic root
thrombus, outflow graft twist or link, in flow cannula malposition, or pump
thrombosis. TTE helps to assess RV failure, cardiac tamponade and inflow
cannula malposition. Positron emission tomography/computed tomography
(PET/CT) can identify infections of the driveline, pump pocket, and LVAD
components. Outcomes of LVAD supported patient may be enhanced with defined
image acquisition protocols and surveillance, interpretation protocols aligned with
current standards and prospective multicenter studies to better understand the
impact on outcomes. Echocardiography remains plays a critical role to determine
ventricular size/function, valvular function and resting intra-cardiac hemodynamics.
Preliminary observational data suggest strategies aimed at optimizing
hemodynamics while on LVAD support meaningfully impacts quality of life and
clinical outcomes. Cardiac CT permits visualization of the inflow and outflow
cannula, aortic root and intra-cardiac structures. PET/CT imaging provides
accurate information on the location and extent for LVAD specific or related
infection and has clinical management and outcome implications.
Left ventricular flow dynamics, unloading, and risk of thrombosis are influenced by
LVAD inflow cannula placement.24, 25 Techniques for 3D printed exoskeleton of the
LVAD inflow cannula can guide proper positioning of the cannula. Personalized,
reproducible and standardized method for optimal inflow cannula position has
been evaluated clinically with positive results. Computer-aided individual patient
specific 3D reconstruction of the complete left ventricle and Computational Fluid
Dynamic (CFD) and 3D printing was used. The method can be used with every
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surgical technique and all types of LVADs. This method should allow for increased
patient safety and widen LVAD indications to lower risk patients.
The theoretical benefits of avoiding cardiopulmonary bypass during LVAD
implantation are a reduction in inflammatory activation, consumption of coagulation
factors, and less bleeding that minimizes blood transfusion, pulmonary vascular
resistance and right heart failure. Also, shorter operative and hospitalization time
may lead to better survival. Off-pump LVAD implantation has a number of
limitations that limit ability to address anatomic and surgical issues. Clinical studies
indicate that off-pump LVAD implantation is feasible and technically not too
challenging. There is less postoperative bleeding which may lead to less right
heart dysfunction, improved outcomes and shorter length of hospital stay. New
surgical tools may improve the technique of off-pump implantation.
In a randomized clinical trial, heart failure hospitalizations were less in patients
managed with guidance from an implantable pulmonary artery pressure sensor
(CardioMEMS) compared with usual care.26 The 12-month survival rate is
significantly better for patients monitored by the CardioMEMS device. Trends in
pulmonary artery pressure allow for careful management of heart failure therapy
that avoids decompensation and hospitalization. Future application of the
CardioMEMS technology with continuous pulmonary artery pressure monitoring
incorporated with LVAD support may offer the ability to support patients with a
“smart pump”.
Total implantation of durable MCS systems with coplanar energy transfer (CET)
have the potential to improve outcomes of LVAD supported patients by elimination
of the percutaneous driveline.27 Energy to power LVAD pumps is transferred
across the skin to an internal coil ring and to a battery. Two initial implants have
been performed as a bridge to transplant with the Jarvik 2000 LVAD. One patient
was discharge from the hospital and eventually underwent successful heart
transplant. The second patient suffered a stroke and had the LVAD
decommissioned. The CET system functioned without significant problems in both
patients.

Novel Technologies
The development objectives for MCS at Abbott is to reduce adverse events,
improve patient’s quality of life, decrease surgical complexity and improve patient’s
medical management. The basis for improved hemocompatibility is with full
MagLev technology in the CentriMag and HeartMate 3 devices. The HeartMate
Touch Communication System is designed to be simple, robust and intelligent

The VAD Journal: 2019 BHFF Conference Proceedings Summary

Page 13 of 23

The VAD Journal: The journal of mechanical assisted circulation and heart failure

using wireless Bluetooth technology. Communication through the Merlin.net
Patient Care Network will allow for remote patient monitoring of patients with MCS.
Incorporation of continuous pulmonary artery pressure monitoring with the
HeartMate 3 and enhanced communication leads to “smart pump” applications in
the future.
The focus of MCS research and development at Medtronic is to improve patient
experience and management, reduce adverse events, and improve patient’s
quality of life. The philosophy behind the new peripherals is to improve the patient
experience and safety. The controller and battery are integrated into one unit
which improves patient usability and significantly reduces weight. Patient
experience is enhanced with actionable warnings and ease of use. The new
peripherals will be Carelink connected for remote patient monitoring. Carelink
enables remote access to waveforms, logfile data and device operating
parameters. A fully implantable LVAD system is being developed and incorporates
multiple components including implantable rechargeable battery, telemetry, and
microelectronics.
The Syncardia Total Artificial Heart (TAH) is now available in 50cc and 70cc sizes
and there are three models of system drivers. The 50cc model is most suiotable
for small adults and pediatrics. One of the major limiting factors in TAH adoption is
the perceived debilitating quality of life caused by the current Freedom driver
system. The new generation Freedom XQs offers a vast upgrade to its
predecessor, eliminating the value proposition of a better quality of life that VADs
offer and consequently, should dramatically improve TAH usage.
The Realheart TAH is based on the action of the natural atrio-ventricular valve
plane motion for efficient cardiac function. Bench, laboratory testing and animal
studies over the past 20 years have produce a well-functioning TAH system. There
is low shear stress, low areas of blood flow stagnation, and there is good
hemocompatibility. Twenty-six large animal studies have been completed showing
adequate hemodynamic support and this is a silent pulsatile pump, cardiac output
and pulse curve is similar to humans, and may potentially be used as a LVAD,
RVAD or BIVAD. The device is somewhat large and weighs 85 grams. The auto
mode functions to provide physiologic cardiac support. The pump now ready for
long term animal experiments.
The LibreCardia ventricular assist system contains a magnetically levitated,
centrifugal blood pump, has no valve, seals, or mechanical bearings, and has a
two-piece outer shell and impeller/rotor containing the magnet. This system is fully
implantable with a small controller/battery and transcutaneous power delivery to
the implanted components. The system also uses a mobile charging unit and a
handheld patient monitor. Initial animal studies have been conducted in 2 bovine
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and 2 ovine. The average pump flow was maintained between 4.5 and 5.5 lpm at
1.5 watts power. Study results showed the device was well tolerated in the juvenile
bovine model for up to 7 days, there was stable and reliable hematological and
biochemical performance, and the receiver coil did not show tissue damage
related to heat injury
A novel disruptive method for the treatment of chronic heart failure called Cardiac
MICrocurrent (C-MIC; Berlin Heals) was introduced. The basis of treatment is an
increase in cardiomyocyte proliferation rate by microcurrent. The leads used for
microcurrent application are a left ventricular epicardial patch and a RV
intraventricular coil. The device size is small and is similar to a pacemaker. Acute
and chronic experiments in sheep have demonstrated an increase in cardiac
output induced by microcurrent therapy and the therapy appears safe. The initial
clinical studies in 8 patients are ongoing with results pending.

Challenges in Heart Transplantation
The purpose of the change in the 2018 UNOS heart allocation system are to better
stratify the most medical urgent transplants, reflect the increased use of MCS and
the prevalence of complications, and to address geographic disparities in access
to donors. Modifications have been made to status 1A, 1B and 2 criteria. More
information is needed regarding wait list mortality, primary graft dysfunction,
survival rates and cost.
There is a learning curve on the use of ECMO as a bridge to heart transplant or
implantation of a durable LVAD. The options for patients with INTERMACS profile
1 heart failure are a temporary LVAD (percutaneous or central) with or without a
temporary right ventricular assist device (RVAD) as a bridge to decision, VAECMO as a bridge to transplant, or a durable LVAD with or without a temporary
RVAD as a bridge to decision or transplant. Based on published studies, ECMO as
a bridge to transplant is possible with a transplant rate of 75% to 80%, and posttransplant survival is less for ECMO supported patients (70% vs 80% at 1 year).
Post-transplant complications of ECMO supported patients include a higher risk of
dialysis, stroke and poor functional status.
Are we ready for the widespread use of hepatitis C viremic (HCV) donors in heart
transplantation? Approximately 2% of US heart transplants in U.S. between 1994 –
2003 had HCV donors. Recipients of HCV positive donors were more likely to die
of viral hepatitis or liver failure (13.7% vs. 0.4%).28 Multiple direct acting antivirals
have been available since 2014 with sustained virologic response >95%
depending on HCV genotype and prior treatment exposure. This therapy is well
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tolerated and there is a low incidence of drug interactions; no interaction with
immunosuppressive medications. In the U.S., these drugs are approved only for
treatment of chronic HCV infection. Practical considerations prior to
implementation of direct acting antiviral therapy must include collaboration with
transplant infectious diseases or hepatology for protocol development, drug
dosing, patient follow-up, and infrastructure for insurance preauthorization.
The Molecular Microscope® Diagnostic System (MMDx) is a central diagnostic
system that uses microarrays to measure transcript changes in biopsies compared
to a Reference Set, using an ensemble of up to 100 predefined machine-learning
derived algorithms (classifiers), supervised and unsupervised to define the
molecular phenotype and interpret the disease states and their severity. Studies
showed the abnormal molecular phenotypes are associated with specifically
different hemodynamic profiles and good correlation for acute cellular rejection
between pathology and MMDx output, but current classification is inadequate to
capture a significant proportion of relevant rejections. The old 1B grade is most
likely associated with antibody mediated rejection-like molecular profile. Current
ISHLT grading system needs to be revised and an integrated approach including
molecular diagnostics and immunopathology may help to improve the diagnostic
precision of rejection.
An evaluation of the impact of a pharmacist-led tacrolimus dose adjustment
protocol on outcomes in de-novo heart transplant recipients has not revealed
significant practice changes. The pharmacist-led standardized tacrolimus dosing
protocol did not decrease the time to therapeutic level as compared to standard
physician adjustment. If anything, the protocol-based algorithm resulted in a
slightly longer time to therapeutic level although no statistical difference was noted,
and the sample size was small. The pharmacist led protocol did increase the
proportion of time in therapeutic range by 17.9% (equal to 2.5) days (p=0.003). It is
too early to reach any conclusion regarding the long-term success of this project.
However, the plan is to increase the treatment arm/derivation cohort to
approximately 50-60 patients in order to ensure racial, gender, and muscle
mass/size diversity. Also, to develop a mobile app for point of care management of
tacrolimus dosing based upon pre-defined patient attributes

Challenges in Transplantation and Heart Failure
Management
Because cardiac and renal disease are physiologically related and often coexist,
the prevalence of combined heart and kidney transplantation (HKTx) has
significantly increased over the last few years. It has been suggested that
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combined organ allografts modulate the immune system favorably for one or both
allografts resulting in successful clinical outcomes. A “safety net” is priority kidney
transplantation for those patients who undergo heart transplant alone and who
develop persistent renal allograft dialysis or GFR<20 for at least 60 days after the
heart alone transplant. There should be aggressive exploration and discussion for
living related kidney donors to occur early in the evaluation process for combined
heart/kidney to maximize opportunities for evaluation and utilization of such
donors; thus, decreasing the impact on the cadaveric renal pool. There is not a
recommendation of an age cut off for heart/kidney transplant candidacy or donor
candidacy as it could prevent potentially eligible recipients from transplantation
and eliminate potentially suitable organs from the pool.
Heart-lung transplant indications include Eisenmenger`s syndrome,
primary/secondary pulmonary hypertension, pulmonary atresia/hypoplasia, and
advanced cardiopulmonary disease. The number of heart-lung transplants for both
adults and pediatrics reported to the ISHLT registry has declined considerably in
recent years. The post-transplant morbidity and survival rates have improved over
time, while the long-term survival remains poor.
The worldwide donor shortage for allotransplantation is a growing problem. As the
number of heart transplant candidates grows, there is not an increase in available
donors. The number of transplants in North America are increasing slightly as the
number in Europe are declining. Xenotransplantation is a potential solution to the
donor shortage; however, achieving long-term survival in pig-to-primate models is
challenging. The main challenges are perioperative cardiac xenograft dysfunction,
delayed rejection, thrombotic microangiopathy, consumptive coagulopathy, and
graft overgrowth. Six-month survival in the baboon model has been achieved, but
this must be extended to 1-year. There must be prevention of transspecies
infection, and ethical challenges remain for the introduction of xenotransplantation
in humans.
Cytomegalovirus (CMV) infection is the most prevalent viral infection after heart
transplant and occur in 40% to 60% of recipients. It most likely occurs in the first 6
months after transplant. The different clinical presentations of CMV infection are
asymptomatic viremia, non-specific viral syndrome and tissue-invasive disease.
CMV infection can exert direct and indirect effects with increased morbidity and
mortality. CMV prophylaxis after transplant can consist of virostatic prophylaxis or
preemptive therapy. There is no universal consensus on optimal CMV prophylaxis
or treatment strategy, or the duration of virostatic therapy. Quantiferon-CMVguided virostatic prophylaxis is safe and may lead to fewer late CMV infection
episodes. CMV-guided approach may lead to a longer virostatic prophylaxis
exposure, but is not unavoidably related to higher incidence of leukopenia.
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Advances in cancer treatment have improved survival rates of patients with
cancer. However, several treatment agents have increased morbidity and mortality
due to cardiotoxic effects. Anthracycline is most frequently associated with
cardiotoxicity, but new agents can also generate significant left ventricular
dysfunction and progress to heart failure. Side effects of this therapy may include
myocardial ischemia, hypertension, arrhythmias and heart failure. Endomyocardial
biopsy confirms cardiotoxicity diagnosis and is the most sensitive and specific
diagnostic tool. Also, cardiac biopsy may identify other causes of cardiac injury
and help define further treatment.
Traditionally, ECG is used to triage acute coronary syndrome patients into
categories of evolving STEMI, NSTEMI, or no myocardial infarction (MI). The
universal definition of MI is based on myocardial injury detected by abnormal
serum cardiac biomarkers, primarily cTn, in the setting of acute myocardial
ischemia. The definition has undergone four iterations over 18 years – 2000, 2007,
2012, 2018. The universal definition currently provides a structured construct for
the differential diagnosis of AMI of various types versus other causes of emergent
clinical presentations in order to guide therapeutic decision making. However,
illustrative cases have shown the complexity of the application of a universal
definition and the contribution of clinicopathological correlation to improving the
diagnostic accuracy of the universal definition of MI in clinical practice.

Innovations in Heart Failure Management
Aspirin has been used as a pain reliever, fever depressant, and, more recently, as
an antiplatelet agent. It was originally made from willow bark extract but is now
made from salicylic acid (sodium calculate). Hippocrates was the first scientist to
prescribe bark tree leaves as a pain reliever. A German scientist that lived in Bayer
Germany was the first person to stabilize acetylsalicylic acid when he used it to
relieve his father’s rheumatism in 1897. Today, aspirin is often used in combination
with anticoagulants to prevent thrombosis in CV disease. Triple therapy (oral
anticoagulant, clopidogrel and aspirin) for percutaneous coronary intervention
(PCI) in atrial fibrillation leads to unacceptable bleeding. Possibly, aspirin may be
avoided, and a lower oral anticoagulant dose could be used. The most recent
guidelines recommend that patients with atrial fibrillation undergoing PCI should
use triple therapy for the shortest period that is clinically acceptable (i.e. 1-mo).
The balance between bleeding and thrombotic risk must be taken into account.
Specific pharmacological management, mostly focused on neurohormonal
suppression, is to improve outcomes in all patients with heart failure and a reduced
ejection fraction. No treatment has been shown to convincingly reduce morbidity
and mortality in patients with heart failure and a normal ejection fraction. Modifier
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genes have been independently associated with the severity and progression of
the disease. Several studies have suggested that some patients have a different
response to treatment due to underlying genetic differences. Polymorphisms in
many genes lead to variability in effectiveness and safety of drugs used in heart
failure treatment. Future studies are needed to determine whether
pharmacogenetic-guided interventions that encompasses multiple genes and
drugs can be implemented clinically to tailor heart failure therapy individually to
achieve better clinical outcomes and lower healthcare costs.
Sarcopenia (muscle weakness/loss) plus obesity carries a high mortality in the
heart failure population. When compared to non-sarcopenic patients, those with
sarcopenia have low body mass index, hemoglobin and albumin, indicative of a
poor nutritional state. Obesity and sarcopenia negatively impact the outcomes of
patients implanted with a durable LVAD. Weight loss for this population of patients
is extremely challenging and compounded by heart failure symptoms of volume
overload, shortness of breath, and fatigue resulting in an extremely limited ability
for physical activity. For most patients, diet and exercise alone are not enough.
Gastric bypass, gastrectomy, banding and biliopancreatic switch are surgical
procedures for helping obese patients lose weight. In our studies, patients
undergoing LVAD implant in the presence of sarcopenia, have longer lengths of
stay in the ICU, and there is a trend towards an increased number of days on
mechanical ventilation.

Future Improvements, Challenges and Solutions
Currently, durable MCS has a survival rate approaching that of heart transplant,
adverse event rates remain high, quality of life is good but could be better, and
growth in use is slowing. The main improvements needed for technology
advancement are enhanced hemocompatibility, reduced infection, improved
durability, and expanded functionality. Substantial improvements in
hemocompatibility have been experienced with the HeartMate 3.29 Wireless energy
transmission for power and control of implanted pumps has the potential to reduce
infectious complications.27 Overall improvements in surgical, medical and
outpatient management need refinements to improve outcomes. Lowering
anticoagulation levels during long-term support has the potential to reduce
bleeding while keeping stroke rates low. Earlier implantation of LVADs and
matching technology to patients can help to improve the patient factors influencing
outcomes.
The first patient to receive a heart transplant in 1967 survived for only 18 days. By
the end of 1968, there had been 102 heart transplants in 50 institutions in 17
countries with a 60% 8-day mortality and mean survival of 29 days. Despite the
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unofficial “moratorium” on heart transplantation after 1968, about 12-15 centers
around the world continued to pursue both experimental and clinical heart
transplantation. Since 1982, well over 100,000 heart transplants have been
performed with increasing survival rates over time.30 The current limitations of
transplant are failures due to both over-immunosuppression (malignancy, infection,
CKD) and under-immunosuppression (acute/chronic rejection), significant non-fatal
morbidities, and the severe supply/demand mismatch. The future of the heart
transplant field must include improved immunosuppression and increasing the
donation rate and utilization. Improvements in outcomes continue but are
incrementally small. Focusing on reducing infections, malignancy and renal failure
will likely improve long-term outcomes more than our traditional focus on acute
rejection and allograft vasculopathy.
Influenza and bacterial (e.g. pneumococcal) pneumonia (the most common
complication of influenza) together are the fifth leading cause of death among
Americans over the age of 65 years. Several epidemiological studies have
suggested that vaccination against seasonal influenza virus infection significantly
reduces the risk of major CV events in patients with acute coronary syndrome or
coronary artery disease. The molecular mechanism underlying the cardioprotective
effect of the influenza vaccine is unknown. Studies in animals and healthy human
volunteers are underway to better understand the cardioprotective mechanisms of
the influenza vaccine.
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